Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic MDST
Time: 16:21:59
Mid Price: 14.25
Change Today: -0.25 Descending
Change % Today: -1.72 Descending
Fifty Two Week High: 54.75
Fifty Two Week Low: 4.00
Market Capital: 22.16
Period & price data
Period Price
Now: 14.25
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: AIM
Sector: Software & Computer Services
Epic: MDST
News: Latest news
Web Site: Medicsight
Other Articles: 25-06-200905-06-200915-05-2009

Medicsight

Medicsight Plc is a UK-headquartered research driven developer of computer-aided detection (CAD) and image analysis software for the medical imaging market, engaged in the development and commercialization of medical imaging software, which analyses Computer Tomography (CT) scans for the early detection and measurement of colon cancer polyps and lung cancer lesions. The Company is also engaged in the research and development of other medical software applications and devices with potential applications in the medical imaging, detection and diagnosis sectors. On June 28, 2007, Medicsight PLC acquired the entire share capital of Medicexchange PTY Ltd from Medicexchange (International) Ltd.
CLICK HERE FOR FULL ANLAYSIS OF MEDICSIGHT
Tuesday, September 23, 2008

Medicsight's ColonCAD Product receives boost from colon cancer study

company news image

Medicsight (AIM: MDST), the image analysis software company, announced that a National US Computerised Tomography (CT) Colonography Trial had boosted the prospects of its ColonCAD Product.

The trial reported that CE Colonography can detect 90% of asymptomatic patients with colonic polyps or cancers of 10 millimetres and larger, and 78% of patients who had a polyp or cancer of 6 millimetres or larger.. The study looked at 2531 asymptomatic patients over the age of 50 who were at an average risk of developing colon cancer.

Medicsight stated that the results of the study are expected to lead to a greater adoption of CT colonography as a routine screening examination for colorectal cancer.   Medicsight’s  ColonCAD Product is targeted at this market.

David Sumner, CEO of Medicsight, commented:  

“We are delighted with the results of this study, which confirms our belief in CTC as a non-invasive alternative to optical colonoscopy for the screening of colon cancer. The level of sensitivity that can be achieved for the detection of polyps is extremely high, and because of its non-invasive nature we believe there will be a greater uptake of this type of screening in the future for those at greatest risk of developing colon cancer.  We predict that Medicsight’s ColonCAD product will be a direct beneficiary of this trend towards utilising CTC as the colon cancer screening modality of choice”



NewsNow icon AddThis Feed Button
Register here to be notified of future Medicsight articles.

Other Medicsight articles


Other Medicsight news

More news ►

Investors interested in Medicsight recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.